A pharmaceutical composition for treating Alzheimer's disease and a preparation method thereof

Abstract

The present invention relates to the technical field of pharmaceutical compositions, and in particular to a pharmaceutical composition for treating Alzheimer's disease and a preparation method thereof. Specifically, it is prepared from the following components by mass: 0.4-0.8 parts of butylphthalide, 0.3-0.7 parts of donepezil hydrochloride, 22-26 parts of ginkgo flavonoids, 30-40 parts of ginsenosides, 16-20 parts of gastrodia elata extract, 13-17 parts of codonopsis pilosula extract, 16-20 parts of raw dragon bone extract, 12-16 parts of calamus tatarinowii extract, 11-15 parts of astragalus extract, 10-16 parts of rhizoma anemarrhenae extract and 15-19 parts of trumpet creeper extract. The pharmaceutical composition provided by the present invention has an excellent effect in treating Alzheimer's disease, can cure patients with early Alzheimer's disease, can effectively alleviate their symptoms and prolong the life of patients with late Alzheimer's disease, and its therapeutic effect is significantly better than that of existing drugs.

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical compositions, and in particular to a pharmaceutical composition for treating Alzheimer's disease and a preparation method thereof. Background Art

[0002] Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive impairment and memory damage. It is the most common form of Alzheimer's disease. Clinically, Alzheimer's disease is characterized by global dementia such as memory impairment, aphasia, agnosia, visual-spatial skill impairment, executive dysfunction, and personality and behavioral changes. Statistics show that one AD patient is added every 7 seconds in the world. AD has become one of the main diseases affecting the health of the elderly, and the effective prevention and treatment of AD has become a major issue facing scholars.

[0003] Alzheimer's disease is complex, has a long course, and has many stages of onset, requiring long-term medication. Currently, the main anti-Alzheimer's drugs include acetylcholinesterase inhibitors (such as galantamine) and N-methyl-D-aspartate receptor (NMDA receptor) antagonists (such as memantine), but the above drugs are expensive, and have significant side effects such as hallucinations, confusion, dizziness, headaches, and fatigue after taking the drugs. They can only control the disease but cannot reverse the patient's condition.

[0004] At present, Western medicine intervention targeting a specific pathological link of AD often leads to drug resistance and serious adverse reactions. Chinese medicine compositions have the characteristics of multiple active components and multiple targets, which makes it promising to screen drug candidates for the treatment of AD from the treasure trove of Chinese medicine compositions. However, although Chinese medicine has the characteristics of no side effects and multiple targets, it still has the disadvantages of long time to take and slow effect.

[0005] Therefore, how to provide a pharmaceutical preparation for treating AD that can combine traditional Chinese medicine and Western medicine to solve the defects of drugs for treating AD in the prior art is a problem that those skilled in the art need to solve urgently. Summary of the invention

[0006] The object of the present invention is to provide a pharmaceutical composition for treating Alzheimer's disease and a preparation method thereof.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] The invention provides a pharmaceutical composition for treating Alzheimer's disease, which is prepared from the following components in parts by weight: 0.4-0.8 parts of butylphthalide, 0.3-0.7 parts of donepezil hydrochloride, 22-26 parts of ginkgo flavonoids, 30-40 parts of ginsenosides, 16-20 parts of gastrodia elata extract, 13-17 parts of codonopsis pilosula extract, 16-20 parts of keel extract, 12-16 parts of calamus tatarinowii extract, 11-15 parts of astragalus extract, 10-16 parts of anemarrhena asphodeloides extract and 15-19 parts of trumpet creeper extract.

[0009] Preferably, the ginsenosides are ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rh1 and ginsenoside Rh2.

[0010] Preferably, the mass ratio of ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rh1 and ginsenoside Rh2 is 9-13:10-14:5-9:7-11:6-10.

[0011] The present invention also provides a method for preparing the pharmaceutical composition for treating Alzheimer's disease, comprising the following steps:

[0012] (1) respectively mixing Gastrodia elata, Codonopsis pilosula, Raw dragon bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides and Campsis crassifolia with ethanol, performing reflux extraction, and filtering to obtain a filtrate;

[0013] (2) decompressing and concentrating the filtrate in step (1), and drying to obtain an extract of Gastrodia elata, an extract of Codonopsis pilosula, an extract of Os Dracaena draco, an extract of Acorus calamus, an extract of Astragalus membranaceus, an extract of Anemarrhena asphodeloides, and an extract of Campsis creeper;

[0014] (3) The Gastrodia elata extract, Codonopsis pilosula extract, Ossobucus scoparia extract, Acorus calamus extract, Astragalus membranaceus extract, Anemarrhena asphodeloides extract, and Campsis creeper extract obtained in step (2) are mixed with butylphthalide, donepezil hydrochloride, ginkgo flavonoids, and ginsenosides to obtain a pharmaceutical composition for treating Alzheimer's disease.

[0015] Preferably, in step (1), the mass ratio of Gastrodia elata, Codonopsis pilosula, Raw dragon bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides, Campsis creeper to ethanol is 1:4-8.

[0016] Preferably, the temperature of the reflux extraction in step (1) is 82-88° C., and the time of the reflux extraction is 2-4 h.

[0017] Preferably, the reflux extraction in step (1) is performed 1 to 3 times.

[0018] Preferably, the volume concentration of ethanol in step (1) is 75-85%.

[0019] Preferably, the extract of step (2) has a relative density of 1.25 to 1.35 when concentrated under reduced pressure to 55°C.

[0020] Preferably, the drying temperature in step (2) is 70-76° C. and the drying time is 2-4 hours.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] 1. The pharmaceutical composition provided by the present invention has an excellent effect in treating Alzheimer's disease. It can cure patients with early-stage Alzheimer's disease and effectively alleviate the symptoms of patients with late-stage Alzheimer's disease and prolong the life of patients. Its therapeutic effect is significantly better than that of drugs in the prior art.

[0023] 2. Among the components added in the present invention, butylphthalide and donepezil hydrochloride both have the effect of treating Alzheimer's disease. The present invention uses the two together to further enhance their efficacy.

[0024] 3. The codonopsis added by the present invention is sweet and flat in nature, invigorates the spleen and lungs, nourishes blood and produces body fluid, and is mainly used for spleen and lung qi deficiency, fatigue due to poor appetite, cough and asthma, qi and blood deficiency, etc. Codonopsis contains chemical components such as polysaccharides, alkaloids, triterpenes, phenylpropanoids, sterols, etc., which have multiple pharmacological effects such as regulating immunity, regulating gastrointestinal function, anti-oxidation, and anti-tumor. Raw dragon bone, flat in nature, sweet and astringent in taste, belongs to kidney meridian, heart meridian, and liver meridian, and has the effects of subduing yang, consolidating, calming the nerves, and stopping diarrhea and sedation. Campsis glomerata, cold in nature, pungent and sour in taste, belongs to liver meridian and pericardium meridian, and has the effects of promoting blood circulation and detoxification, cooling blood and dispelling wind, and removing swelling and dispersing blood stasis.

[0025] Ginkgo flavonoids can promote circulation, anti-aging, and anti-oxidation, and have a certain improvement on dementia, Alzheimer's disease and memory. Ginsenosides can enhance physical fitness and are suitable for patients with physical weakness. It can also regulate nerves. Ginsenosides have a significant effect on the central nervous system, can calm the mind, provide nutrition for neurons, and improve the function of the central nervous system. Gastrodia elata enters the liver meridian, and its medicinal properties are mild. It has the effects of calming the liver and extinguishing wind, calming the nerves and calming the nerves. It can treat epilepsy, head wind, stroke and other diseases caused by liver deficiency, and can better relieve dizziness and vertigo. If children have epilepsy, hot phlegm and convulsions, they will have symptoms such as polyphagia and trance. Acorus calamus has the effect of regulating qi and activating blood circulation, which can promote blood circulation, improve symptoms such as chest distress, qi stagnation and deafness, and traumatic injuries. Acorus calamus can also play a role in dispersing wind and dampness, and is suitable for patients with wind-cold and dampness. In addition, Acorus calamus enters the heart meridian and has the effect of awakening the mind and opening the orifices. Astragalus has a certain effect on the prevention and treatment of Alzheimer's disease. Astragalus has the effects of invigorating qi and strengthening the exterior, promoting diuresis and removing toxins, and draining pus. It is used for qi deficiency and fatigue, sinking of middle qi, chronic diarrhea and prolapse of the anus, spontaneous sweating due to exterior deficiency, edema due to qi deficiency, long-term ulcers that do not heal, or internal heat and thirst, etc. It can also wake up the brain and open the mind, and nourish the essence and nourish the marrow. Anemarrhena has the effects of nourishing yin and moistening the lungs, moistening the intestines and relieving constipation, and anti-inflammatory and gallbladder. The present invention adds a variety of plant extract components, which can not only further enhance the efficacy of the drug, but also reduce the use of chemical drugs and reduce the side effects caused by chemical drugs. DETAILED DESCRIPTION

[0026] The present invention provides a pharmaceutical composition for treating Alzheimer's disease, which is prepared from the following components in parts by weight: 0.4-0.8 parts of butylphthalide, 0.3-0.7 parts of donepezil hydrochloride, 22-26 parts of ginkgo flavonoids, 30-40 parts of ginsenosides, 16-20 parts of gastrodia elata extract, 13-17 parts of codonopsis pilosula extract, 16-20 parts of keel extract, 12-16 parts of calamus tatarinowii extract, 11-15 parts of astragalus extract, 10-16 parts of anemarrhena asphodeloides extract and 15-19 parts of trumpet creeper extract;

[0027] Preferably, the invention is prepared from the following components in parts by weight: 0.5-0.7 parts of butylphthalide, 0.4-0.6 parts of donepezil hydrochloride, 23-25 ​​parts of ginkgo flavonoids, 32-38 parts of ginsenosides, 17-19 parts of gastrodia elata extract, 14-16 parts of codonopsis pilosula extract, 17-19 parts of keel extract, 13-15 parts of calamus tatarinowii extract, 12-14 parts of astragalus extract, 11-15 parts of anemarrhena asphodeloides extract and 16-18 parts of trumpet creeper extract;

[0028] It is further preferably prepared from the following components in parts by weight: 0.6 parts of butylphthalide, 0.5 parts of donepezil hydrochloride, 24 parts of ginkgo flavonoids, 34-36 parts of ginsenosides, 18 parts of Gastrodia elata extract, 15 parts of Codonopsis pilosula extract, 18 parts of Dracaena draco extract, 14 parts of Acorus calamus extract, 13 parts of Astragalus membranaceus extract, 12-14 parts of Anemarrhena asphodeloides extract and 17 parts of Campsis creeper extract;

[0029] More preferably, it is prepared from the following components in parts by mass: 0.6 parts of butylphthalide, 0.5 parts of donepezil hydrochloride, 24 parts of ginkgo flavonoids, 35 parts of ginsenosides, 18 parts of Gastrodia elata extract, 15 parts of Codonopsis pilosula extract, 18 parts of Dracaena draco extract, 14 parts of Acorus calamus extract, 13 parts of Astragalus membranaceus extract, 13 parts of Anemarrhena asphodeloides extract and 17 parts of Campsis creeper extract.

[0030] In the present invention, the ginsenosides are ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rh1 and ginsenoside Rh2.

[0031] In the present invention, the mass ratio of ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rh1 and ginsenoside Rh2 is 9-13:10-14:5-9:7-11:6-10; preferably 10-12:11-13:6-8:8-10:7-9; further preferably 11:12:7:9:8.

[0032] The present invention also provides a method for preparing the pharmaceutical composition for treating Alzheimer's disease, comprising the following steps:

[0033] (1) respectively mixing Gastrodia elata, Codonopsis pilosula, Raw dragon bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides and Campsis crassifolia with ethanol, performing reflux extraction, and filtering to obtain a filtrate;

[0034] (2) decompressing and concentrating the filtrate in step (1), and drying to obtain an extract of Gastrodia elata, an extract of Codonopsis pilosula, an extract of Os Dracaena draco, an extract of Acorus calamus, an extract of Astragalus membranaceus, an extract of Anemarrhena asphodeloides, and an extract of Campsis creeper;

[0035] (3) The Gastrodia elata extract, Codonopsis pilosula extract, Ossobucus scoparia extract, Acorus calamus extract, Astragalus membranaceus extract, Anemarrhena asphodeloides extract, and Campsis creeper extract obtained in step (2) are mixed with butylphthalide, donepezil hydrochloride, ginkgo flavonoids, and ginsenosides to obtain a pharmaceutical composition for treating Alzheimer's disease.

[0036] In the present invention, the mass ratio of Gastrodia elata, Codonopsis pilosula, Raw dragon bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides, Campsis creeper to ethanol in step (1) is 1:4-8; preferably; more preferably; more preferably.

[0037] In the present invention, the temperature of the reflux extraction in step (1) is 82-88°C, preferably 83-87°C, more preferably 84-86°C, and more preferably 85°C.

[0038] In the present invention, the reflux extraction time in step (1) is 2 to 4 hours, preferably 3 hours.

[0039] In the present invention, the number of reflux extraction in step (1) is 1 to 3 times, preferably 3 times.

[0040] In the present invention, the volume concentration of ethanol in step (1) is 75-85%; preferably 77-83%; more preferably 79-81%; and more preferably 80%.

[0041] In the present invention, the relative density of the extract when concentrated under reduced pressure to 55° C. in step (2) is 1.25 to 1.35; preferably 1.27 to 1.33; more preferably 1.29 to 1.31; and more preferably 1.30.

[0042] In the present invention, the drying temperature in step (2) is 70-76°C, preferably 71-75°C, more preferably 72-74°C, and more preferably 73°C.

[0043] In the present invention, the drying time in step (2) is 2 to 4 hours, preferably 3 hours.

[0044] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0045] Example 1

[0046] A method for preparing a pharmaceutical composition for treating Alzheimer's disease, comprising the following steps:

[0047] (1) Gastrodia elata, Codonopsis pilosula, raw dragon bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides, and Campsis crassifolia were mixed with 75% ethanol in a mass ratio of 1:4, and refluxed at 82°C for 2 h, for a total of 1 extraction, and filtered to obtain a filtrate;

[0048] (2) decompressing and concentrating the filtrate in step (1) to an extract having a relative density of 1.25 at 55° C.; drying the extract at 70° C. for 2 h to obtain an extract of Gastrodia elata, an extract of Codonopsis pilosula, an extract of Ossobucus scoparia, an extract of Acorus tatarinowii, an extract of Astragalus membranaceus, an extract of Rhizoma Anemarrhenae, and an extract of Campsis creeper;

[0049] (3) mixing 16 parts of the Gastrodia elata extract obtained in step (2), 13 parts of Codonopsis pilosula extract, 16 parts of Ossobucus scoparia extract, 12 parts of Acorus calamus extract, 11 parts of Astragalus membranaceus extract, 10 parts of Anemarrhena asphodeloides extract, 15 parts of Campsis creeper extract, 0.4 parts of butylphthalide, 0.3 parts of donepezil hydrochloride, 22 parts of Ginkgo biloba flavonoids and 30 parts of ginsenosides to obtain a pharmaceutical composition for treating Alzheimer's disease;

[0050] The mass ratio of ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rh1 and ginsenoside Rh2 is 9:10:5:7:6.

[0051] Example 2

[0052] A method for preparing a pharmaceutical composition for treating Alzheimer's disease, comprising the following steps:

[0053] (1) Gastrodia elata, Codonopsis pilosula, Raw dragon bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides and Campsis crassifolia were mixed with 85% ethanol in a mass ratio of 1:8, and refluxed for extraction at 88°C for 4 h, for a total of 3 times, and filtered to obtain a filtrate;

[0054] (2) decompressing and concentrating the filtrate in step (1) to an extract having a relative density of 1.35 at 55° C.; drying the extract at 76° C. for 4 h to obtain an extract of Gastrodia elata, an extract of Codonopsis pilosula, an extract of Dracaena draco, an extract of Acorus tatarinowii, an extract of Astragalus membranaceus, an extract of Anemarrhena asphodeloides and an extract of Campsis creeper;

[0055] (3) mixing 20 parts of the Gastrodia elata extract obtained in step (2), 17 parts of the Codonopsis pilosula extract, 20 parts of the Dracaena draco extract, 16 parts of the Acorus calamus extract, 15 parts of the Astragalus membranaceus extract, 16 parts of the Anemarrhena asphodeloides extract, 19 parts of the Campsis creeper extract, 0.8 parts of butylphthalide, 0.7 parts of donepezil hydrochloride, 26 parts of ginkgo flavonoids and 40 parts of ginsenosides to obtain a pharmaceutical composition for treating Alzheimer's disease;

[0056] The mass ratio of ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rh1 and ginsenoside Rh2 is 13:14:9:11:10.

[0057] Example 3

[0058] A method for preparing a pharmaceutical composition for treating Alzheimer's disease, comprising the following steps:

[0059] (1) Gastrodia elata, Codonopsis pilosula, Raw dragon bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides and Campsis crassifolia were mixed with 80% ethanol in a mass ratio of 1:6, and refluxed for extraction at 85°C for 3 h, for a total of 2 extractions, and filtered to obtain a filtrate;

[0060] (2) decompressing and concentrating the filtrate in step (1) to an extract having a relative density of 1.30 at 55° C.; drying the extract at 73° C. for 3 h to obtain an extract of Gastrodia elata, an extract of Codonopsis pilosula, an extract of Dracaena draco, an extract of Acorus calamus, an extract of Astragalus membranaceus, an extract of Anemarrhena asphodeloides and an extract of Campsis creeper;

[0061] (3) mixing 18 parts of the Gastrodia elata extract obtained in step (2), 15 parts of the Codonopsis pilosula extract, 18 parts of the Dracaena draco extract, 14 parts of the Acorus calamus extract, 13 parts of the Astragalus membranaceus extract, 13 parts of the Anemarrhena asphodeloides extract, 17 parts of the Campsis creeper extract, 0.6 parts of butylphthalide, 0.5 parts of donepezil hydrochloride, 24 parts of ginkgo flavonoids and 35 parts of ginsenosides to obtain a pharmaceutical composition for treating Alzheimer's disease;

[0062] The mass ratio of ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rh1 and ginsenoside Rh2 is 11:12:7:9:8.

[0063] Experimental Example 1

[0064] a. Preparation of dementia rat model

[0065] Modeling drug Aβ 1-42 Dementia model. 1-42 Dissolve in 0.9% NaCl to make 1 μg / μL -1 The solution was incubated for 12 hours before use. The SD rats were weighed, and according to the different body weights, 5% chloral hydrate (0.5 ml / 100 g) was injected intraperitoneally to anesthetize the rats. The anesthetized rats were accurately fixed on the double-arm brain stereotaxic instrument, and the local hair on the top of the head was removed with curved scissors, and iodine was used for disinfection. A 3 cm midsagittal incision was made to separate and peel off the periosteum, and the positions of the anterior and posterior fontanelles of the SD rats were observed and kept on the same horizontal plane. The anterior fontanelle was positioned at 0, and the bilateral parahippocampal gyri were taken as the injection target points (3.0 mm behind the anterior fontanelle, 2.2 mm on both sides, and 2.8 mm below the dura mater), and a vertical hole was drilled, and 5 μL Aβ was slowly injected along the hole with a microsyringe. 1-42 The solution was injected into the bilateral parahippocampal gyrus. After the injection, the needle was left in place for about 5 minutes on each side and the incision was sutured.

[0066] b. Experimental grouping and drug administration: Drug administration began 24 hours after modeling.

[0067] The normal group and the model group were gavaged with normal saline;

[0068] The positive group was perfused with donepezil hydrochloride (purchased from Eisai (China) Pharmaceutical Co., Ltd.) (1 mg / kg);

[0069] The product obtained by the method of Example 3 was used as the experimental group;

[0070] Control group 1, other methods were the same as those in Example 3, except that donepezil hydrochloride was not used;

[0071] Control group 2, other methods were the same as Example 3, except that ginsenoside was not used;

[0072] Control group 3, other methods were the same as those in Example 3, except that ginkgo flavonoids were not used;

[0073] Control group 4, other methods were the same as those in Example 3, except that no Codonopsis pilosula extract was used;

[0074] Control group 5, other methods are the same as those in Example 3, except that the mass ratio of ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rh1 and ginsenoside Rh2 is 1:1:1:1:1.

[0075] The dosage of the experimental group and control group 1 to control group 5 is: 30 mg / kg body weight / d.

[0076] Eight rats were treated in each experimental group for 1 month. Male Sprague-Dawley (SD) rats aged 6 weeks (200 ± 15 g) were purchased from the Medical Laboratory Animal Center of Daping Hospital, Third Military Medical University (Chongqing, China). Rats were housed in a specific pathogen-free facility. All experiments were performed in accordance with the “Regulations on the Administration of Laboratory Animals” promulgated by the State Science and Technology Commission of the People’s Republic of China.

[0077] c. Behavioral evaluation (Morris water maze) of spatial memory changes in rats in different groups

[0078] The Morris water maze is an experiment in which mice are placed in a designated swimming area and, after a period of learning, they search for a hidden platform in the water. Related instruments are used to observe and record their activity tracks and the time required to find the platform. It mainly tests the mice's ability to locate in space and judge direction, thereby reflecting their learning and memory abilities.

[0079] Positioning navigation test: Two series of training were conducted every day, morning and afternoon, for a total of 16 times. The rats were placed in the water facing different quadrants of the pool wall, and the time it took to find and climb onto the platform within 120 seconds (i.e., escape latency) was recorded, as well as the distance traveled.

[0080] Spatial exploration test: After the positioning navigation experiment, the platform was removed, and then the rat was placed into the water facing the pool wall at any entry point, and the number of times the rat crossed the original platform within 120 seconds was recorded.

[0081] The test results of each test group were averaged and the results are shown in Table 1.

[0082] Table 1 Survey results

[0083]

[0084] Compared with the normal group, the learning and memory abilities of the rats in the model group were significantly reduced, as shown by the significantly prolonged escape latency and distance in the Morris water maze test, and the significantly reduced number of crossing the original platform, indicating that the animal modeling of this experiment was successful. Compared with the model group, after the experimental group was given drug treatment, the rats' escape latency and distance were shortened, and the number of crossing the original platform increased, indicating that the composition provided by the present invention has the effect of treating Alzheimer's disease, and the treatment effect is better than the existing drugs.

[0085] From the data of control groups 1 to 5, it can be seen that the components of the present invention work synergistically. If some of the components are discarded, the therapeutic efficacy of the drug will be significantly affected. For ginsenosides, only by adopting the ratio setting of the present invention can the best therapeutic effect be achieved.

[0086] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A pharmaceutical composition for treating Alzheimer's disease, characterized in that: The invention is prepared from the following components in parts by weight: 0.4-0.8 parts of butylphthalide, 0.3-0.7 parts of donepezil hydrochloride, 22-26 parts of ginkgo flavonoids, 30-40 parts of ginsenosides, 16-20 parts of gastrodia elata extract, 13-17 parts of codonopsis pilosula extract, 16-20 parts of keel extract, 12-16 parts of calamus tatarinowii extract, 11-15 parts of astragalus extract, 10-16 parts of anemarrhena asphodeloides extract and 15-19 parts of trumpet creeper extract; The ginsenosides are ginsenoside Rb2, ginsenoside Rb3, ginsenoside Rd, ginsenoside Rh1 and ginsenoside Rh2, with a mass ratio of 9-13:10-14:5-9:7-11:6-10; Gastrodia elata, Codonopsis pilosula, Raw dragon bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides and Campsis creeper are respectively mixed with ethanol, refluxed for extraction, and filtered to obtain a filtrate; the filtrate is concentrated under reduced pressure and dried to obtain Gastrodia elata extract, Codonopsis pilosula extract, Raw dragon bone extract, Acorus calamus extract, Astragalus membranaceus extract, Anemarrhena asphodeloides extract and Campsis creeper extract.

2. The method for preparing a pharmaceutical composition for treating Alzheimer's disease according to claim 1, characterized in that: The steps include: (1) respectively mixing Gastrodia elata, Codonopsis pilosula, Raw dragon bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides and Campsis crassifolia with ethanol, performing reflux extraction, and filtering to obtain a filtrate; (2) decompressing and concentrating the filtrate in step (1), and drying to obtain Gastrodia elata extract, Codonopsis pilosula extract, Ossobucus scoparia extract, Acorus calamus extract, Astragalus membranaceus extract, Rhizoma Anemarrhenae extract, and Campsis creeper extract; (3) The Gastrodia elata extract, Codonopsis pilosula extract, Ossobucus scoparia extract, Acorus tatarinowii extract, Astragalus membranaceus extract, Anemarrhena asphodeloides extract, and Campsis creeper extract obtained in step (2) are mixed with butylphthalide, donepezil hydrochloride, ginkgo flavonoids, and ginsenosides to obtain a pharmaceutical composition for treating Alzheimer's disease.

3. The method for preparing a pharmaceutical composition for treating Alzheimer's disease according to claim 1, characterized in that: In step (1), the mass ratio of the Gastrodia elata, Codonopsis pilosula, Raw Dragon Bone, Acorus calamus, Astragalus membranaceus, Anemarrhena asphodeloides, Campsis creeper to ethanol is 1:4-8.

4. A method for preparing a pharmaceutical composition for treating Alzheimer's disease according to claim 2 or 3, characterized in that: The temperature of the reflux extraction in step (1) is 82-88° C. and the time of the reflux extraction is 2-4 h.

5. The method for preparing a pharmaceutical composition for treating Alzheimer's disease according to claim 2, characterized in that: The number of reflux extractions in step (1) is 1 to 3 times.

6. A method for preparing a pharmaceutical composition for treating Alzheimer's disease according to claim 2 or 5, characterized in that: The volume concentration of ethanol in step (1) is 75-85%.

7. The method for preparing a pharmaceutical composition for treating Alzheimer's disease according to claim 2, characterized in that: The extract of step (2) having a relative density of 1.25-1.35 when concentrated under reduced pressure to 55°C.

8. The method for preparing a pharmaceutical composition for treating Alzheimer's disease according to claim 2, characterized in that: The drying temperature in step (2) is 70-76° C. and the drying time is 2-4 hours.

Images